Q2 2026 Quarterly Update — Free Live Webinar

Free Live Webinar · Wednesday, April 22nd, 2026 · 1:30 PM Eastern

The April 1st Reset

Just Changed Your Numbers.

Do You Know Your New Total?

Every April 1st, orphan drug manufacturer pricing resets — and most CAHs, SCHs, and RRCs miss the window entirely. In this free 60-minute webinar, Rev. Dr. Lisa Nezneski, PharmD, BCPS walks you through exactly what changed, what it means for your facility, and how to capture every dollar available to you in Q2 2026.

🗓️ Date

Wednesday, April 22nd, 2026

🕐 Time

1:30 PM Eastern

⏱️Duration

60 Minutes

💻 Platform

Live via Demio

Q2 Alert The April 1st orphan drug pricing reset is one of the most overlooked savings windows in the 340B calendar. Manufacturers restructured discretionary pricing programs on April 1st — and facilities that don't act within 60–90 days lock in suboptimal savings for the entire quarter. This webinar is your briefing.

4 Things That Changed on April 1st at Your Facility

Every new quarter brings a cascade of changes to your orphan drug program — pricing, formularies, manufacturer policies, and HRSA lists. Here's what reset when the calendar flipped to Q2 2026:

01
Manufacturer Pricing Restructured
Discretionary pricing agreements don't auto-renew. April 1st triggered new manufacturer price schedules — and facilities without current agreements are paying ceiling price or above.
02
New HRSA Orphan Drug List Effective
The Q1 2026 FDA orphan drug designation changes are now reflected in the HRSA list. New designations mean new savings opportunities. Rescinded designations mean exposure.
03
Q1 Purchase File Deadline Window
Q1 2026 purchases need to be reconciled and submitted. Many facilities are sitting on unprocessed files — which means uncaptured savings are evaporating daily.
04
Split Biller Configuration Risk
Outdated split biller configurations are the #1 source of missed orphan drug savings. After every pricing reset, configuration drift widens.

In 60 Minutes, You'll Walk Away With Real Numbers

This is not a theory webinar. Every point maps directly to line items on your drug spend report. Bring your Q1 purchase data and get ready to find your money.

  • The April 1st Pricing Reset BreakdownExactly which manufacturers reset their orphan drug programs on April 1st, what the new structures look like, and which facilities are already capturing the difference — and which are not.
  • The 6 Money Buckets — Q2 EditionThe specific places savings hide at every facility reviewed — including what's uniquely shifted in Q2 2026. In 12 years of reviews, there has never been a facility with zero hidden savings.
  • The Q1 Purchase File Action PlanHow to process, reconcile, and submit your Q1 orphan drug purchase file correctly — and the specific errors that cause facilities to leave $30K–$80K on the table.
  • The Split Biller Audit — 5-Minute VersionThe fastest way to check if your split biller configuration is costing you $100K–$400K annually. We'll show you exactly where to look and what to ask your vendor.
  • The Manufacturer Negotiation Most Facilities SkipOne phone call — the discretionary pricing conversation most CAH and SCH pharmacy directors never make — that is routinely worth $25,000 to $50,000+ per drug.
  • Your Q2 2026 Savings Estimate FrameworkLeave with a concrete method to calculate your facility's likely uncaptured Q2 savings — before you even schedule a discovery call.

This Webinar Is Built for Expansion Entity Leaders

340B Orphan Drug Solutions works exclusively with CAHs, SCHs, and RRCs. This is not a general 340B webinar. Every minute is specific to your entity type, your drug portfolio, and your Q2 2026 opportunity window.

Critical Access Hospital (CAH)
Sole Community Hospital (SCH)
Rural Referral Center (RRC)
Pharmacy Director / PharmD
CFO / CEO / 340B Coordinator
Authorizing Official
Hospital Administrator
New to orphan drug optimization
Currently "optimized" but unsure
Not for: DSH-only hospitals, FQHCs without expansion entity status, or facilities already working with 340B Orphan Drug Solutions. This is a new-client and prospective-partner briefing.

Childcare Solutions

We provide a safe, nurturing, and engaging environment where children feel valued and supported every day. Our staff ensures your child’s social, emotional, and educational growth.

Nutritious Meals

Healthy bodies fuel healthy minds. We serve freshly prepared, balanced meals and snacks designed to meet children’s nutritional needs and encourage lifelong healthy eating habits.

Experiential Learning

Hands-on activities, creative play, and guided exploration help children learn by doing. We encourage curiosity, imagination, and problem-solving through structured and free play.

What You’ll Experience in This Webinar

This is not a sales pitch. This is a real conversation.

Join me for a candid sit-down interview with Flaviu Simihaian, Co-Founder of Aventi Health — the only founder-owned 340B TPA in the country. Flaviu will walk us through how Aventi was built differently, who it was built for, and why small hospitals and FQHCs are at the center of everything they do.

You’ll get:

  • A live platform demo — see Aventi’s technology in action, built for simplicity and speed

  • A frank discussion on 340B TPA pricing why most models are designed against small hospitals — and what Aventi does differently

  • Real talk about customer service — what it actually means to have direct access to the founders

  • Live Q&A — bring your toughest questions — Flaviu will answer them on air

  • Insight into onboarding timelines — how fast can you actually get up and running?

Your Host

Meet Rev. Dr. Lisa Nezneski

Founder & CEO · 340B Orphan Drug Solutions

Lisa Nezneski is the only consultant in the country working exclusively in 340B orphan drug optimization for expansion entities. With 12 years of specialized expertise — and 40+ years in healthcare — she has reviewed facilities across the country and achieved a 100% findings rate: every single facility reviewed has had uncaptured savings. Her approach is direct, data-driven, and built entirely around the financial reality of CAH, SCH, and RRC operations.

© 2026 340B Orphan Drug Solutions. All rights reserved.